R3TA 60MG

How It Works

• Triple-Receptor Activation: Unlike older medications that target one or two receptors, retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. 

• Appetite & Satiety: GLP-1 and GIP pathways slow stomach digestion and signal fullness in the brain. 

• Energy Expenditure: The glucagon receptor component helps speed up metabolism and break down fat cells. 

Clinical Trial Results

• Weight Loss: Phase 3 clinical trials show impressive dose-dependent weight reductions, with average weight loss reaching up to approximately 28% to 30% of starting body weight over extended periods